CD8A and neoplasm: Using the experimental mouse models of renal cell cancer and MethA sarcoma, intratumoral administration of DCs, genetically modified to express IL-12, IL-21 or IFNα, demonstrated potent therapeutic effects against established tumors with the induction of potent tumor antigen-specific CD8+ T-cell responses and increased CD4+ and CD8+ T cell infiltration in tumors [115].